The Company, domestically and internationally developing, outsourcing manufacturing and distributing health and beauty products under brands Rojukiss, Best Korea, and Sis2Sis with over 100 SKUs in our product portfolio
| 6M23 | 6M22 | 2022 | 2021 |
|---|
| Revenues | 447.04 | 365.19 | 940.06 | 776.05 |
| Expenses | 356.18 | 308.76 | 764.84 | 629.80 |
| Net Profit (Loss) | 72.16 | 49.90 | 123.71 | 118.57 |
| Assets | 1,336.49 | 1,197.90 | 1,297.08 | 1,048.73 |
| Liabilities | 289.53 | 242.69 | 278.55 | 118.81 |
| Shareholders' Equity | 974.69 | 926.32 | 964.06 | 929.92 |
| Operating | 24.49 | 67.35 | 85.54 | 177.95 |
| Investing | -0.83 | -111.17 | -111.03 | -187.74 |
| Financing | -28.04 | -27.69 | -89.57 | 370.52 |
| EPS (Baht) | 0.09 | 0.08 | 0.21 | 0.20 |
| GP Margin (%) | 53.81 | 53.82 | 51.97 | 53.57 |
| NP Margin (%) | 16.14 | 13.67 | 15.73 | 15.28 |
| D/E Ratio (x) | 0.28 | 0.25 | 0.27 | 0.13 |
| ROE (%) | 13.37 | 10.22 | 13.06 | 17.47 |
| ROA (%) | 16.64 | 9.62 | 15.61 | 16.08 |
- Uplifting the company's products to be the "Top of Mind Brand" through advertising and marketing activities, together with the development of consumer-responsive product innovation
- Expanding distribution channels for color cosmetic products under the Sis2Sis brand
- Enhancing sales channels both Offline and Online
- Growing in overseas markets by planning strategies and setting appropriate business models to accelerate growth and enhance competitiveness
- Adapting strategic plans for health products to the circumstances at hand
KISS is committed to operating business in line with a sustainable development approach as well as considering all relevant stakeholders in tune with good governance principles. We support sustainable development through the foundation of our business operations based on ESG principles, which encompass the environmental social, and governance dimensions. The organization's sustainability policy was created to guide its strategy and ability to do business in a socially responsible manner, under the mission to be a global leader in the future beauty and health business in Asia will be reignited (Health & Beauty for the Future of Asia). For further information, please visit our website. https://hub.optiwise.io/storage/103/annual-report/2022/e-book/th/index.html
The company’s started to expand business into the healthcare market under the trademarked Vaill CoviTRAP TM Anti-CoV Nasal Spray, which has been widely accepted by health-conscious consumers especially during the Covid-19 outbreak. This is considered as a further move toward becoming a leader in Asia’s health & beauty business for the future.
Revenue from sales and services was 445.5 million baht, an increase of 23.4% from the same period of the previous year. The growth was mainly from domestic sales, driven by solid sales growth from skincare and color cosmetic products at a growth rate of 27.3% across all channels as a result of new product launches and the support of marketing activities. While nasal spray products have demonstrated consistent growth, reflecting the overall performance has increased significantly. In terms of overseas, there is still intense competition in this market. Nonetheless, the Company is in the process of adjusting its strategic plan and expanding its market to other countries.
While Net Profit was 72.2 million baht , an increase of 44.6% from the last year from sales growth of existing product and new product launches as well as the expansion of distribution channels that reach consumers, and full marketing activities along with the effective in cost and selling and administrative expenses management.
2020
- Launched new skin beauty supplement under “Rojukiss”
- Signed with the company's products distributor in Indonesia and the Philippines.
- Registered as a public company: Increase registered capital to prepare for an IPO and expand business continuously.
2021
- Release new products to export for sale to Indonesia.
- Release new products to export for sale to Vietnam
2022
- Investment in Hibiocy Company Limited to expand its business into Health product innovations and launched “VAILL COVITRAP Anti-CoV” Nasal Spray under the management of Hibiocy Co., Ltd. (“HIB”)
The Company has put in place risk management system and process throughout the organization which is in line with business strategies and goals. The Company assigns responsibilities for risk control and review the risk measures annually by setting guidelines that cover the assessment in the following main topics:
- Strategic & Brand Risk
- Operational & Supply Chain Risk
- Financial & Liquidity Risk
- Information Technology Risk
- Organizational Risk
- Compliance Risk
The company received an Outstanding CEO award from the IAA Awards for Listed Companies 2022 please visit our website. https://investor.rojukissinternational.com/en/newsroom/press-releases/81248/kiss-received-outstanding-ceo-from-iaa-awards-2022
| as of 30/06/23 | KISS | PERSON | SET |
|---|---|---|---|
| P/E (X) | 27.01 | 22.37 | 17.96 |
| P/BV (X) | 3.57 | 0.96 | 1.46 |
| Dividend yield (%) | 2.37 | 5.97 | 3.12 |
| 30/06/23 | 30/12/22 | 30/12/21 | |
|---|---|---|---|
| Market Cap (MB) | 3,540.06 | 5,100.00 | 6,300.00 |
| Price (B/Share) | 5.90 | 8.50 | 10.50 |
| P/E (X) | 27.01 | 48.87 | 49.59 |
| P/BV (X) | 3.57 | 5.49 | 6.93 |
